Literature DB >> 3762696

A novel selective broad-spectrum anti-DNA virus agent.

E De Clercq, A Holý, I Rosenberg, T Sakuma, J Balzarini, P C Maudgal.   

Abstract

A new compound has been found, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine ((S)-HPMPA), that has potent and selective activity against a broad spectrum of DNA viruses, including herpes simplex virus (types 1 and 2); varicella zoster virus; thymidine kinase-deficient (TK-) mutants of herpes simplex and varicella zoster virus; human cytomegalovirus; phocid, simian, suid, bovid and equid herpesviruses; African swine fever virus; vaccinia virus; and human adenoviruses. It is also active against retroviruses. We also report that, in mice and rabbits in vivo, the compound is effective against both local and systemic infections with herpes simplex virus type 1, including herpetic keratitis caused by a TK- mutant which is resistant to the classical anti-herpes drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3762696     DOI: 10.1038/323464a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  118 in total

1.  -CH2- lengthening of the internucleotide linkage in the ApA dimer can improve its conformational compatibility with its natural polynucleotide counterpart.

Authors:  J Hanus; I Barvík; K Ruszová-Chmelová; J Stepánek; P Y Turpin; J Bok; I Rosenberg; M Petrová-Endová
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

2.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

Review 4.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

5.  Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.

Authors:  Valeria M Zakharova; Michaela Serpi; Ivan S Krylov; Larryn W Peterson; Julie M Breitenbach; Katherine Z Borysko; John C Drach; Mindy Collins; John M Hilfinger; Boris A Kashemirov; Charles E McKenna
Journal:  J Med Chem       Date:  2011-08-03       Impact factor: 7.446

6.  Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.

Authors:  Karl Y Hostetler; Kathy A Aldern; William B Wan; Stephanie L Ciesla; James R Beadle
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 7.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 8.  Alpha-carboxynucleoside phosphonates: direct-acting inhibitors of viral DNA polymerases.

Authors:  Jan Balzarini; Alan Ford; Nuala M Maguire; Jubi John; Kalyan Das; Eddy Arnold; Wim Dehaen; Anita Maguire
Journal:  Future Med Chem       Date:  2019-01-16       Impact factor: 3.808

Review 9.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

10.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.